Physician profile
Mark T Winders
NPI 1306899364
$3,552.56
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $73.27 · 2021: $439 · 2022: $796 · 2023: $936 · 2024: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.61 | 2021-2024 | Vraylar, Qulipta |
| Pfizer INC. | $451.04 | 2019-2024 | |
| Novo Nordisk INC | $445.99 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $353.67 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $227.80 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $227.54 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.29 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $141.18 | 2022 | |
| Esperion Therapeutics, INC. | $97.89 | 2021-2022 | |
| Lilly USA, LLC | $90.44 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $89.22 | 2019-2021 | |
| Exact Sciences Corporation | $73.33 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.46 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $42.33 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.63 | 2024 | Caplyta |
| Ardelyx, INC. | $32.79 | 2024 | Ibsrela |
| Astellas Pharma US INC | $32.05 | 2019-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $29.60 | 2022-2023 | Quviviq |
| Abbott Laboratories | $28.34 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
| Allergan, INC. | $25.33 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $23.65 | 2024 | Voquezna |
| Si-Bone, INC. | $19.25 | 2021 | |
| Abiomed | $17.48 | 2024 | Impella |
| Hologic Sales and Service, LLC | $16.45 | 2021 | |
| Merck Sharp & Dohme LLC | $15.61 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $14.61 | 2019 | |
| Mylan Specialty L.P. | $12.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Winders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.